Table 2.
The clinic trials of MSCs therapy in DM.
| MSCs origins | Number of patients | The key findings | Follow-up period(year) | years | references |
|---|---|---|---|---|---|
| BM-MSCs | 30 (BM-MSCs: 10 BM-MNCs: 10 Control: 10) | Both BM-MSCs and BM-MNCs therapies in T2DM result in significant decreases in insulin dose requirement accompanied by improvement in insulin sensitivity and β-cells function | 1 | 2017 | (61) |
| Umbilical cord-MSCs | 42 (UC-MSCs/BM-MNCs: 21Control: 21) | MSCs/MSCs treatment cause progressive reductions in insulin dose requirements and HbA1c levels and increased fasting C-peptide levels as well as AUCC-Pep | 1 | 2016 | (108) |
| WJ-MSCs | 61 (WJ-MSCs:31 Control:30) | Blood glucose, glycosylated hemoglobin, C-peptide, homeostasis model assessment of pancreatic islet β−cell function, and incidence of diabetic complications in the MSCs group were significantly improved when compared with the control group during the 36 months follow−up in T2DM | 3 | 2016 | (109) |
| WJ-MSCs | 12 (liraglutide+WJ-MSCs:6 liraglutide:6) | liraglutide treatment in combination with WJ-MSCs improves glucose metabolism and the β cell function in T2D patients | 6 months | 2016 | (110) |
| Adipose-MSCs | 20 (AD-MSCs:10 Control:10) | Variable and sustained improvement in mean fasting blood glucose(FBG), post-meal blood glucose(PBG), HbA1c, and serum C-peptide was noted after the treatment of insulin-secreting mesenchymal stromal cell. | 2 | 2015 | (111) |
| BM-MSCs | 20 (MSCs:10 Insulin treatment:10) | Autologous MSC treatment of new-onset type 1 diabetes may be a safe and feasible strategy to intervene in the disease process and preserve β-cell function | 1 | 2015 | (112) |
| WJ-MSCs | 6 | Following transplantation, no immediate or delayed toxicity associated with the cell administration, and the levels of fasting C-peptide, the peak value and the area under the C-peptide release curve increased significantly within one month and remained high during the follow-up period | 2 | 2015 | (113) |
| Umbilical cord-MSCs | 18 | FBG and PBG were significantly reduced and plasma C-peptide levels and regulatory T (Treg) cell number were numerically higher after UMSC transfusion in T2D patients. | 6 months | 2014 | (114) |
| WJ-MSCs | 22 | WJ-MSC transplantation decreased the level of HbA1c, increased the level of fasting C-peptide, decreased the FBG, 2h-postprandial blood glucose level, insulin requirement, and oral hypoglycemic drugs; and reduced the systemic inflammation and T lymphocyte counts in patients with T2DM | 1 | 2014 | (53) |
| WJ-MSCs | 29 (WJ-MSCs:15 Control:14) | No reported acute or chronic side effects in the MSCs group compared with the control group, both the HbA1c and C peptide in MSCs group patients were significantly better than either pre-therapy values or control group patients during the follow-up period in T1DM. | 2 | 2013 | (115) |
| Placenta-MSCs | 10 | The mean levels of insulin and C-peptide at each time point in a total of 10 patients were higher and the renal function and cardiac function were improved after MSCs infusion, indicating that transplantation of placenta-MSC represents a simple, safe and effective therapeutic approach for T2D patients with islet cell dysfunction | 1 | 2011 | (116) |
| Adipose-MSCs | 11 | Transplantation of insulin-secreting cells that differentiated from AM-MSCs decreased insulin requirement and Hb1Ac levels and serum C-peptide levels were improved in T1D patients. | 2 | 2010 | (117) |